Glucolipotoxicity is an important phenomenon combining the deleterious effects of elevated glucose and fatty acid levels on pancreatic β-cell function and survival. It is a key element in Human Type 2 diabetes’ pathophysiology. It impairs insulin secretion, inhibits insulin gene expression and induces β-cell death by apoptosis. Combining strengths of GLTx Endoc-BH5® cells with ADAPT® platform capacity to generate unique pathophysiological disease models, GLTx assay recapitulates glucolipotoxicity in vitro. This assay enables you to assess the pharmacological efficacy of your drug discovery strategies aiming to protect human beta cells and slow the progression of insulin secretion dysfunction due to glucolipotoxicity.